Controlled release hydrocodone formulations

Patent metadata

Field	Value
Publication number	US-9320717-B2
Application number	US-201514672894-A
Country	US
Kind code	B2
Filing date	Mar 30, 2015
Priority date	Oct 29, 1999
Publication date	Apr 26, 2016
Grant date	Apr 26, 2016

Abstract

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C 12 /C max ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

First claim

We claim:

1. A twice-a-day solid oral controlled-release dosage form of a pharmaceutically acceptable salt of hydrocodone, the dosage form comprising:
a therapeutically effective amount of a pharmaceutically acceptable salt of hydrocodone, and
two different types of multiparticulates in the form of granules, spheroids, or pellets,
a first type of said multiparticulates comprising a first portion of the pharmaceutically acceptable salt of hydrocodone and providing an immediate release of hydrocodone,
a second type of said multiparticulates comprising a remaining portion of the pharmaceutically acceptable salt of hydrocodone and at least one pharmaceutically acceptable excipient and providing a controlled release of hydrocodone,
the dosage form providing an in-vitro release of from at least 18% to about 42.5% by weight of hydrocodone from the dosage form at one hour when measured by the USP Basket Method at 100 rpm in 700 ml of Simulated Gastric Fluid (SGF) for 55 minutes at 37° C. and thereafter switching to 900 ml of Simulated Intestinal Fluid (SIF) at 37° C., and
after a first administration to a human, providing a plasma concentration of hydrocodone of at least 8 ng/ml at from about 2 to about 8 hours after administration and a plasma concentration of hydrocodone of at least 6 ng/ml at about 12 hours after administration, based on oral administration of a dosage form containing 15 mg hydrocodone bitartrate,
a C 12 /C max hydrocodone ratio of 0.55 to 0.85 and
a T max of hydrocodone at from about 2 to about 8 hours, wherein
the therapeutically effective amount of the pharmaceutically acceptable salt of hydrocodone is from about 5 mg to about 60 mg, and
the salt of hydrocodone is an inorganic salt of hydrocodone or a bitartrate salt of hydrocodone.

2. The dosage form of claim 1 , which is a capsule.

3. The dosage form of claim 1 , which provides a C 12 /C max hydrocodone ratio of 0.65 to 0.75 after said first administration.

4. A twice-a-day solid oral controlled-release dosage form comprising multiparticulates collectively comprising an amount of a pharmaceutically acceptable salt of hydrocodone equivalent to from about 0.5 mg to about 1250 mg of hydrocodone,
the dosage form providing an in-vitro release of from 18% to about 42.5% by weight of hydrocodone from the dosage form at one hour when measured by the USP Basket Method at 100 rpm in 700 ml of Simulated Gastric Fluid (SGF) for 55 minutes at 37° C. and thereafter switching to 900 ml of Simulated Intestinal Fluid (SIF) at 37° C., and,
after a first administration to a human population, providing a mean plasma concentration of hydrocodone of at least 8 ng/ml at from about 2 to about 8 hours after administration and a plasma concentration of hydrocodone of at least 6 ng/ml at about 12 hours after administration, based on oral administration of a dosage form containing 15 mg hydrocodone bitartrate,
a mean C 12 /C max hydrocodone ratio of 0.55 to 0.85,
a mean T max of hydrocodone of from about 2 to about 8 hours, and
a therapeutic effect for about 12 hours, wherein
at least one multiparticulate comprises a gum, and
the pharmaceutically acceptable salt of hydrocodone is selected from the group consisting of bitartrate salts of hydrocodone, hydrocodone hydrochloride, hydrocodone p-toluenesulfonate, hydrocodone phosphate, hydrocodone thiosemicarbazone, hydrocodone sulfate, hydrocodone trifluoroacetate, hydrocodone hemipentahydrate, hydrocodone pentafluoropropionate, hydrocodone p-nitrophenylhydrazone, hydrocodone o-methyloxime, hydrocodone semicarbazone, hydrocodone hydrobromide, hydrocodone mucate, hydrocodone oleate, hydrocodone phosphate dibasic, hydrocodone phosphate monobasic, hydrocodone oleate, trihydrate, hydrocodone bis(heptafuorobutyrate), hydrocodone bis(methylcarbamate), hydrocodone bis(pentafluoropropionate), hydrocodone bis(pyridine carboxylate), hydrocodone bis(trifluoroacetate), hydrocodone chlorhydrate, and hydrocodone sulfate pentahydrate.

5. The dosage form of claim 4 , which is a capsule.

6. The dosage form of claim 4 , which is a tablet.

7. The dosage form of claim 4 , which provides a C 12 /C max hydrocodone ratio of 0.65 to 0.75 after said first administration.

8. The dosage form of claim 4 , which is a capsule comprising from about 5 mg to about 60 mg of hydrocodone bitartrate.

9. The dosage form of claim 4 , wherein each multiparticulate has a diameter of between 0.1 mm and 2.5 mm.

10. The dosage form of claim 1 , which provides a C 12 /C max hydrocodone ratio of 0.65 to 0.75 after said first administration.

11. The dosage form of claim 1 , which is a capsule comprising from about 5 mg to about 60 mg of hydrocodone bitartrate.

12. The dosage form of claim 1 , wherein the pharmaceutically acceptable salt of hydrocodone is hydrocodone bitartrate.

13. The dosage form of claim 4 , wherein the pharmaceutically acceptable salt of hydrocodone is hydrocodone bitartrate.

Assignees

• Purdue Pharma Lp

Inventors

• Oshlack Benjamin
• Huang Hua-Pin
• Masselink John
• Tonelli Alfred P

Classifications

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/2846

  Poly(meth)acrylates · CPC title

• A61K9/2018

  Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates · CPC title